Epimedin C (flavonol glycoside)

Epimedin C is a prenylated flavonol glycoside derived from Epimedium species (horny goat weed) that exerts neuroprotective and anti-inflammatory effects primarily by activating the Nrf2/HO-1 antioxidant signaling pathway. It also inhibits NF-κB-mediated inflammatory cascades and shares structural similarity with icariin, the benchmark bioactive compound of Epimedium.

Origin & History

Epimedin C is a flavonol glycoside isolated from Epimedium species (horny goat weed), a traditional medicinal plant native to China and Southeast Asia. It is extracted from the aerial parts of the plant using standard solvent extraction and purification techniques.

Historical & Cultural Context

Epimedin C comes from Herba Epimedii (Epimedium), traditionally used in Chinese herbal medicine for treating diabetes and as an edible herb in China and Southeast Asia. The parent plant has historical use for stimulating bone growth, preventing bone loss, and treating neurodegeneration and osteoarthritis.

Health Benefits

• Neuroprotection: Protects nerve cells from oxidative stress by activating Nrf2/HO-1 pathway and reducing apoptosis (preliminary evidence from PC12 cell studies)
• Anti-inflammatory effects: Reduces inflammation in chondrocytes and may benefit osteoarthritis (preliminary evidence from in vitro studies)
• Bone health support: Enhances osteoblast proliferation and protects against dexamethasone-induced damage (preliminary evidence from cell studies)
• Potential diabetes management: Shows hypoglycemic effects in mouse models of type 2 diabetes (preliminary animal evidence)
• Respiratory health: Attenuates inflammation in asthmatic mouse models (preliminary animal evidence)

How It Works

Epimedin C activates the Nrf2/HO-1 (nuclear factor erythroid 2-related factor 2 / heme oxygenase-1) pathway, upregulating antioxidant response elements and reducing reactive oxygen species-mediated apoptosis in neuronal cells. It concurrently suppresses NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) nuclear translocation, thereby reducing downstream pro-inflammatory cytokine production including IL-1β, IL-6, and TNF-α. In chondrocyte models, it inhibits MMP-3 and MMP-13 matrix metalloproteinase expression, potentially protecting cartilage extracellular matrix from degradation.

Scientific Research

No human clinical trials have been conducted on Epimedin C. All available evidence comes from preclinical studies including PC12 cell models showing neuroprotection at 1-10 µM concentrations, chondrocyte studies demonstrating anti-inflammatory effects at 10-20 µM, and various animal models investigating diabetes and asthma.

Clinical Summary

Current evidence for Epimedin C is limited to in vitro cell culture studies and animal models, with no completed human clinical trials specifically isolating this compound. PC12 neuronal cell studies demonstrated reduced hydrogen peroxide-induced apoptosis and increased cell viability through Nrf2/HO-1 activation, though these findings have not been translated to human subjects. In vitro chondrocyte studies showed dose-dependent reductions in IL-1β-stimulated inflammatory markers, suggesting potential osteoarthritis relevance. The overall evidence base is preliminary, and extrapolating these findings to human supplementation requires significant caution until randomized controlled trials are conducted.

Nutritional Profile

Epimedin C is a purified flavonol glycoside compound (prenylflavonoid), not a whole food ingredient, and therefore has no conventional macronutrient or micronutrient profile. Structural composition: molecular formula C38H48O20, molecular weight approximately 820.77 g/mol. It is a prenylated flavonol glycoside consisting of a kaempferol aglycone core with a prenyl (3,3-dimethylallyl) substituent at C-8 and a trisaccharide chain (rhamnose-rhamnose-glucose) at C-3, which classifies it as an icariin-type flavonoid. Naturally sourced from Epimedium species (Yin Yang Huo/Horny Goat Weed) where it co-occurs with related compounds icariin, epimedin A, and epimedin B; typical concentration in Epimedium plant material ranges from 0.1–2.5% dry weight depending on species and plant part. As an isolated compound, it contains no fiber, protein, fat, or micronutrients. Bioavailability is a key limitation: oral bioavailability is low due to poor aqueous solubility (lipophilic prenyl group) and extensive first-pass metabolism; gut microbiota hydrolyze the glycoside to release the aglycone icaritin, which is considered the primary bioactive form. Plasma half-life and peak concentration data remain limited to preliminary pharmacokinetic studies in rodent models. No established dietary reference intake or tolerable upper limit exists.

Preparation & Dosage

No clinically studied human dosages are available. In vitro studies used 1-10 µM for neuroprotection and 10-20 µM for anti-inflammatory effects. No standardized extract forms or human dosing guidelines exist. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Epimedium flavonoids, Nrf2 activators, Anti-inflammatory compounds, Bone health nutrients, Antioxidants

Safety & Interactions

No human safety or tolerability trials have been conducted specifically for isolated Epimedin C, making definitive risk profiling impossible at this time. As a constituent of Epimedium extracts, it may share the class-level concern of potential estrogenic activity, warranting caution in individuals with hormone-sensitive conditions such as estrogen receptor-positive cancers. Epimedium-based products have been associated with rare reports of hepatotoxicity and tachyarrhythmia, though causality for individual glycosides like Epimedin C has not been established. Pregnant or breastfeeding individuals and those taking anticoagulants, hormonal therapies, or cytochrome P450-metabolized drugs should avoid use pending further safety data.